6185 Stock Overview
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People’s Republic of China.
CanSino Biologics Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||HK$78.10|
|52 Week High||HK$437.00|
|52 Week Low||HK$66.70|
|1 Month Change||10.78%|
|3 Month Change||-49.52%|
|1 Year Change||-81.16%|
|3 Year Change||136.67%|
|5 Year Change||n/a|
|Change since IPO||125.07%|
Recent News & Updates
|6185||HK Pharmaceuticals||HK Market|
Return vs Industry: 6185 underperformed the Hong Kong Pharmaceuticals industry which returned -43.6% over the past year.
Return vs Market: 6185 underperformed the Hong Kong Market which returned -21.5% over the past year.
|6185 Average Weekly Movement||10.6%|
|Pharmaceuticals Industry Average Movement||6.2%|
|Market Average Movement||7.0%|
|10% most volatile stocks in HK Market||13.6%|
|10% least volatile stocks in HK Market||3.3%|
Stable Share Price: 6185 is more volatile than 75% of Hong Kong stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: 6185's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People’s Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It also develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination.
CanSino Biologics Fundamentals Summary
|6185 fundamental statistics|
Is 6185 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|6185 income statement (TTM)|
|Cost of Revenue||CN¥1.22b|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||8.30|
|Net Profit Margin||47.32%|
How did 6185 perform over the long term?See historical performance and comparison
1.2%Current Dividend Yield
Is 6185 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 5/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 6185?
Other financial metrics that can be useful for relative valuation.
|What is 6185's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does 6185's PE Ratio compare to its peers?
|6185 PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
Price-To-Earnings vs Peers: 6185 is good value based on its Price-To-Earnings Ratio (8x) compared to the peer average (10.2x).
Price to Earnings Ratio vs Industry
How does 6185's PE Ratio compare vs other companies in the Hong Kong Pharmaceuticals Industry?
Price-To-Earnings vs Industry: 6185 is good value based on its Price-To-Earnings Ratio (8x) compared to the Hong Kong Pharmaceuticals industry average (9.2x)
Price to Earnings Ratio vs Fair Ratio
What is 6185's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||8x|
|Fair PE Ratio||15.8x|
Price-To-Earnings vs Fair Ratio: 6185 is good value based on its Price-To-Earnings Ratio (8x) compared to the estimated Fair Price-To-Earnings Ratio (15.8x).
Share Price vs Fair Value
What is the Fair Price of 6185 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 6185 (HK$78.1) is trading below our estimate of fair value (HK$449.38)
Significantly Below Fair Value: 6185 is trading below fair value by more than 20%.
Price to Earnings Growth Ratio
PEG Ratio: 6185 is poor value based on its PEG Ratio (2.1x)
Discover undervalued companies
How is CanSino Biologics forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 6185's forecast earnings growth (3.9% per year) is above the savings rate (1.5%).
Earnings vs Market: 6185's earnings (3.9% per year) are forecast to grow slower than the Hong Kong market (16.7% per year).
High Growth Earnings: 6185's earnings are forecast to grow, but not significantly.
Revenue vs Market: 6185's revenue (10.4% per year) is forecast to grow faster than the Hong Kong market (10.2% per year).
High Growth Revenue: 6185's revenue (10.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 6185's Return on Equity is forecast to be low in 3 years time (6.8%).
Discover growth companies
How has CanSino Biologics performed over the past 5 years?
Past Performance Score3/6
Past Performance Score 3/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 6185 has a high level of non-cash earnings.
Growing Profit Margin: 6185 became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: 6185 has become profitable over the past 5 years, growing earnings by 83.5% per year.
Accelerating Growth: 6185 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 6185 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (16.1%).
Return on Equity
High ROE: 6185's Return on Equity (23.7%) is considered high.
Discover strong past performing companies
How is CanSino Biologics's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: 6185's short term assets (CN¥9.1B) exceed its short term liabilities (CN¥2.8B).
Long Term Liabilities: 6185's short term assets (CN¥9.1B) exceed its long term liabilities (CN¥579.4M).
Debt to Equity History and Analysis
Debt Level: 6185 has more cash than its total debt.
Reducing Debt: 6185's debt to equity ratio has reduced from 25.3% to 15.3% over the past 5 years.
Debt Coverage: 6185's debt is well covered by operating cash flow (111.6%).
Interest Coverage: 6185 earns more interest than it pays, so coverage of interest payments is not a concern.
Discover healthy companies
What is CanSino Biologics's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 6185's dividend (1.2%) isn’t notable compared to the bottom 25% of dividend payers in the Hong Kong market (2.77%).
High Dividend: 6185's dividend (1.2%) is low compared to the top 25% of dividend payers in the Hong Kong market (7.82%).
Stability and Growth of Payments
Stable Dividend: 6185 is not paying a notable dividend for the Hong Kong market, therefore no need to check if payments are stable.
Growing Dividend: 6185 is not paying a notable dividend for the Hong Kong market, therefore no need to check if payments are increasing.
Earnings Payout to Shareholders
Earnings Coverage: 6185 is not paying a notable dividend for the Hong Kong market.
Cash Payout to Shareholders
Cash Flow Coverage: 6185 is not paying a notable dividend for the Hong Kong market.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Xuefeng Yu (57 yo)
Dr. Xuefeng Yu Co-Founded CanSino Biologics Inc. Dr. Yu was appointed as an Executive Director on January 13, 2009 and has served as the Chief Executive Officer of CanSino Biologics Inc. since January 2009...
Experienced Management: 6185's management team is seasoned and experienced (9 years average tenure).
Experienced Board: 6185's board of directors are considered experienced (4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: 6185 insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
CanSino Biologics Inc.'s employee growth, exchange listings and data sources
- Name: CanSino Biologics Inc.
- Ticker: 6185
- Exchange: SEHK
- Founded: 2009
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: HK$35.558b
- Shares outstanding: 246.95m
- Website: https://www.cansinotech.com
Number of Employees
- CanSino Biologics Inc.
- 401-420, Biomedical Park
- 4th Floor
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/22 00:00|
|End of Day Share Price||2022/06/22 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.